In Vitro Evaluation of the Inhibitory Effect of Topical Ophthalmic Agents on Acanthamoeba Viability

Wayne Heaselgrave¹, Anas Hamad¹², Steven Coles³, and Scott Hau⁴

¹ Department of Biomedical Science & Physiology, University of Wolverhampton, Wolverhampton, UK
² Department of Biology, University of Anbar, Al-Ramadi, P.O. Box 55431, Ramadi, Iraq
³ School of Science & the Environment, University of Worcester, Worcester, UK
⁴ Department of External Disease, National Institute for Health Research-Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK

Purpose: To compare the antimicrobial effect of topical anesthetics, antivirals, antibiotics, and biocides on the viability of Acanthamoeba spp. in vitro.

Methods: Amoebicidal and cysticidal assays were performed against both trophozoites and cysts of Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba polyphaga (ATCC 30461). Test agents included topical ophthalmic preparations of common anesthetics, antivirals, antibiotics, and biocides. Organisms were exposed to serial two-fold dilutions of the test compounds in the wells of a microtiter plate to examine the effect on Acanthamoeba spp. In addition, the toxicity of each of the test compounds was determined against a mammalian cell line.

Results: Proxymetacaine, oxybuprocaine, and especially tetracaine were all toxic to the trophozoites and cysts of Acanthamoeba spp., but lidocaine was well tolerated. The presence of the benzalkonium chloride (BAC) preservative in levofloxacin caused a high level of toxicity to trophozoites and cysts. With the diamidines, the presence of BAC in the propamidine drops was responsible for the activity against Acanthamoeba spp. Hexamidine drops without BAC showed good activity against trophozoites, and the biguanides polyhexamethylene biguanide, chlorhexidine, alexidine, and octenidine all showed excellent activity against trophozoites and cysts of both species.

Conclusions: The antiamoebic effects of BAC, povidone iodine, and tetracaine are superior to the current diamidines and slightly inferior to the biguanides used in the treatment for Acanthamoeba keratitis.

Translational Relevance: Ophthalmologists should be aware that certain topical anesthetics and ophthalmic preparations containing BAC prior to specimen sampling may affect the viability of Acanthamoeba spp. in vivo, resulting in false-negative results in diagnostic tests.
United States and have been attributed to efficacy issue with certain CL disfections system.1, 8

Despite the sight-threatening risk with AK, in most series, it accounts for less than 5% of all CL-related microbial keratitis. The reported incidence rates in CL users are 1 to 2 per million in the United States and 17 to 20 per million in the United Kingdom.4 A recent study from a tertiary hospital in the United States and 17 to 20 per million in the United Kingdom.4 A recent study from a tertiary hospital in the United Kingdom reported an incidence rate of just 2.3% for *Acanthamoeba* over a 12-year period from over 1500 keratitis cases.9 Due to the small number of patients with AK, many are diagnosed late due to initially being misdiagnosed and treated for bacterial or other forms of keratitis, such as fungal and herpes simplex keratitis.4, 10 A late diagnosis of AK has a massive impact on prognosis, and patients are more likely to develop poorer visual outcome, longer duration of treatment, corneal perforation, and the requirement of penetrating keratoplasty.10

Current medical therapy for AK is unlicensed and involves the topical administration of a biguanide, namely, 0.02% polyhexamethylene biguanide (PHMB) or 0.02% chlorhexidine, either as monotherapy or in combination with 0.1% propamidine or 0.1% hexamidine.11 PHMB and chlorhexidine have been reported to be the most effective and are effective against both trophozoites and cysts of *Acanthamoeba*.12-14

In the United Kingdom, the diagnosis of AK is not standardized and depends largely upon individual clinics and hospitals.15 A variety of methods can be used with culture of a corneal scrape on 2.5% nonnutrient agar that has been overlaid with a lawn of *Escherichia coli*, the most common method utilized and considered the gold standard. Despite the wide use of this culture-based method, poor sensitivity means that in many cases the culture comes back negative in patients with the infection. A recent study looking at diagnostic sensitivity reported a value of 33.3% for culture compared to 74.1% and 100% for polymerase chain reaction (PCR) and in vivo confocal microscopy (IVCM), respectively.16

One possibility for the low sensitivity of culture-based diagnostics for *Acanthamoeba* could be related to prior topical therapy, such as anesthetics and antibiotics, applied to the cornea prior to the corneal scrape being performed on the patient. Goldschmidt et al.17 have found that fluorescein and topical anesthetics could interfere with real-time PCR to detect herpesvirus and *Acanthamoeba*, resulting in false-negative results. Other studies have also shown that the use of Rose Bengal and Lissamine green reduced PCR detection rates for herpesvirus and toxoplasma.18 Furthermore, empirical antibiotic treatment with fluoroquinolone drugs or other biocides prior to diagnosis could have an effect on the viability of *Acanthamoeba*. Aside from the antimicrobial drugs, many ophthalmic preparations utilize benzalkonium chloride (BAC) as a preservative, and it has been shown that BAC is highly toxic to *Acanthamoeba*.19

Due to the potential effect of topical anesthetics and antimicrobials on the viability of *Acanthamoeba* cysts and trophozoites, we studied the activity of a range of commonly used topical anesthetics, antibiotics, antivirals, and biocides against the trophozoite and cyst stages of *Acanthamoeba polyphaga* (ATCC 30461) and *Acanthamoeba castellanii* (ATCC 50370) and a mammalian cell line.

**Materials and Methods**

**Reagents and Test Compounds**

We tested a range of ophthalmic preparations, including biocides, diamidines, anesthetics, antivirals, and antibiotics. All agents were obtained from Sigma Chemical Company Ltd. (Poole, UK) unless otherwise stated. The biocides, diamidines, and miscellaneous compounds included Brolene (propamidine isethionate 0.1% w/v; Sanofi, Guildford, UK), Desomedine (hexamidine di-isonetate 0.1%; Bausch & Lomb, Aubenas, France), PHMB (Lonza, Slough, UK), octenidine (Schulke & Mayr, Norderstedt, Germany), chlorhexidine digluconate 0.1% w/v, alexidine 0.1% w/v, propamidine 0.1% w/v, hexamidine 0.1% w/v, pentamidine 0.1% w/v, BAC 0.1% w/v, phenylmercuric nitrate 0.1% w/v, fluorescein sodium 2% w/v (Minims; Bausch & Lomb), and povidone iodide 5% w/v (Minims; Bausch & Lomb). Antibiotics used were preserved levofloxacin 5 mg/ml (Ofthaquix; Santen, St Albans, UK), preservative-free levofloxacin 5 mg/ml (Ofthaquix Unit Dose, Santen), moxifloxacin 0.5% w/v (Moxeza; Novartis, Friemley, UK), preserved chloramphenicol 0.5% w/v (Martindale Pharma, Brentwood, UK), and preservative-free chloramphenicol 0.5% w/v (Minims; Bausch & Lomb). The topical anesthetics were all in Minims formulation (Bausch & Lomb), and they included proxymetacaine (proparacaine) 0.5% w/v, tetracaine 1% w/v, oxybuprocaine 0.4% w/v, and lidocaine 4% w/v with fluorescein sodium 0.25% w/v. Antivirals used were trifluorothymidine (TFT) 1% w/v (Stockport Pharmaceuticals, Stockport, UK) and...
aciclovir 0.1% w/v. All the compounds were stored according to the manufacturers’ recommendations.

**Test Organism Strains and Culture**

*A. castellanii* (ATCC 50370) and *A. polyphaga* (ATCC 30461) were obtained from the American Type Culture Collection (LGC Standards, Teddington, UK). Trophozoites were maintained in a semi-defined axenic broth medium as previously described. Cysts were produced using Neff’s encystment medium (NEM) method as previously described. Trophozoites were seeded into large tissue culture flasks (Nunc, Altringham, UK) at a density of $1 \times 10^5$ cells/ml in 50 ml of growth medium and incubated for 48 hours at 30°C. The trophozoites were harvested by centrifugation at 500 × g for 5 minutes and washed three times with one-fourth-strength Ringer’s solution. The final pellet was then inoculated into 50 ml of NEM at a density of $1 \times 10^6$ cells/ml into tissue culture flasks. The cultures were then incubated at 30°C for 7 days on a shaking incubator. The cysts were harvested for testing after 7 days of incubation in NEM and washed three times with one-fourth-strength Ringer’s solution. The pellet was adjusted to $5 \times 10^6$ cysts/ml by using a modified Fuchs Rosenthal hemocytometer (Hawksley, Lancing, UK), and the cysts were stored at 4 to 8°C for testing within 14 days.

**Amoebicidal Assays**

In the trophozoite assay, serial two-fold dilutions of the test compounds were made in the wells of a tissue culture-grade microtiter plate (Helena Biosciences, Gateshead, UK). Ophthalmic preparation was used straight from the bottle and was serially diluted from the concentration stated on the product information label. Pure drugs were prepared as 1-mg/ml (0.1%) stock solutions in an appropriate solvent. Control wells received one-fourth-strength Ringer’s solution in place of the test solution. Log-phase cultures of axenic trophozoites were adjusted to a concentration of $2 \times 10^4$/ml in growth medium, and 100 μl of the calibrated suspension was added to the wells for incubation at 30°C in triplicate. After 48 hours, the wells were inspected using an inverted microscope. This was achieved by comparing the appearance of the trophozoites in the test wells to those in controls. Typically, this involves visually comparing the degree of amoeba growth relative to the control as well as looking for cell lysis and rounding of the amoebae. The minimum trophozoite inhibitory concentration (MTIC) was defined as 50% inhibition of *Acanthamoeba* trophozoite replication compared to the controls. The minimum trophozoite amoebicidal concentration (MTAC) was defined as the lowest concentration of test compound that resulted in the complete lysis or degeneration of the trophozoites.

**Cysticidal Assays**

The cysticidal assay relies on the observation that *Acanthamoeba* cysts adhere to the well bottoms of the microtiter plates and remain attached following exposure to the test compound and removal by washing. The addition of live *Escherichia coli* to the wells, followed by incubation, results in encystment of viable cysts and replication of the emergent trophozoites. Serial two-fold dilutions of the test compounds were prepared with distilled water in the wells of the microtiter plate. Cysts were adjusted to a final concentration of $2 \times 10^4$ cells/ml in one-fourth-strength Ringer’s solution, and 100 μl was added to each well. The plates were then incubated at 30°C for 48 hours. After the incubation, the wells were aspirated to remove the drug using a Vacusip (Integra, Thatcham, UK) and refilled with one-fourth-strength Ringer’s solution. This process was repeated three times to ensure removal of the drugs from the wells. After the final aspiration, the wells were filled with 100 μl of one-fourth-strength Ringer’s containing live *E. coli* (ATCC 8739) at an optical density of 0.2 at 540 nm and incubated at 30°C. The minimum cysticidal concentration (MCC) was defined as the lowest concentration of test compound that resulted in no excystation and trophozoite replication after 7 days of incubation.

**Hep-2 Cell Cytotoxicity**

The cytotoxicity of the test compounds was determined against the Hep-2 (HeLa derivative) human cervix carcinoma cell line (ECACC number 86030501) obtained from the European Collection of Cell Cultures (Centre for Applied Microbiology and Research, Salisbury, UK). The cells were grown and maintained at 37°C in minimum essential medium with 10% heat-inactivated fetal bovine serum (Life Technologies Ltd., Paisley, Scotland). Flasks containing confluent monolayers of cells were used to seed a 96-well microtiter plate at a concentration of $1 \times 10^4$ cells/well in 100 μl of growth medium with incubation at 37°C. Once approximately 75% confluent growth occurred in the wells, the medium was changed, and
the cells were used for cytotoxicity testing. Serial two-fold dilutions of the test agent in appropriate solvent were added to the wells, and the plate was incubated at 37°C for 24 hours. The degree of cytotoxicity was determined using the CellTiter 96 AQ uous One Solution Cell Proliferation Assay (Promega, Southampton, UK). This is a colormetric assay in which metabolically active cells bioreduce a tetrazolium compound to generate a soluble colored formazan product whose abundance can be measured spectrophotometrically at 595 nm.21

Transmission Electron Microscopy (TEM) of Acanthamoeba Cysts

For the TEM studies, Neff’s cysts of A. castellanii were used. The cysts were exposed to the test formulations by using either topical ophthalmic preparations (tetracaine 1% and preserved chloramphenicol 0.5%) or solutions made up to the same concentration used in ophthalmic preparations (PHMB 0.02%, unpreserved chloramphenicol 0.5%, BAC 0.05 mg/ml, and povidone-iodine 5%). Controls cysts were exposed to one-fourth-strength Ringer’s solution. The cysts were exposed to the test formulations at 32°C for 1 hour. The agents were removed by washing the cysts with one-fourth-strength Ringer’s solution and centrifuged at 1000×g for 5 minutes. The resulting pellets were fixed with 2.5% (v/v) glutaraldehyde buffered with 0.1 M HEPES at pH 7.2 overnight at 4°C before being processed for TEM microscopy.

Results

The activities of the test compounds against the trophozoites and cysts of A. castellanii (ATCC 50370) and A. polyphaga (ATCC 30461) and their toxicity for Hep-2 cells are shown in Tables 1 to 4. The results for the topical anesthetics and fluorescein sodium are shown in Table 1. The inhibitory range against Acanthamoeba trophozoites for the anesthetics proxymetacaine, tetracaine, and oxybuprocaine were 9.75 to 39 μg/ml, whereas lidocaine produced no inhibition of growth until the 312- to 625-μg/ml range for both species. In the trophozoite amoebicidal studies proxymetacaine, tetracaine, and oxybuprocaine were amoebicidal in the 19.5- to 250-μg/ml range, whereas with lidocaine, the amoebicidal activity against A. polyphaga and A. castellanii was 312 and 1250 μg/ml, respectively. For the cyst assays, proxymetacaine, tetracaine, and oxybuprocaine were cysticidal in the 39- to 250-μg/ml range. With lidocaine, the cysticidal activity against A. polyphaga and A. castellanii was 312 and 1250 μg/ml, respectively. For the toxicity assay against the mammalian cell line, proxymetacaine, tetracaine, and oxybuprocaine were cytotoxic in the 39- to 156-μg/ml range, whereas lidocaine produced no cytotoxicity until 5 mg/ml. The lidocaine Minims contains fluorescein sodium and so as a control this was tested separately and found to be nontoxic at the 2% concentration (Table 1).

The results for the topical antibiotics, antivirals, and preservatives are shown in Table 2. For the fluoroquinolones, the levofloxacin (Oftaquix) formulation demonstrated trophozoite inhibitory and amoebicidal activity in the 78- to 312-μg/ml range, whereas for the unpreserved levofloxacin (pure drug without BAC), the values were in the 312- to 1250-μg/ml range for both species, a factor of 4 difference in magnitude from the commercial ophthalmic preparation. Moxifloxacin (Moxeza) demonstrated trophozoite inhibitory and amoebicidal activity in the 625- to 2500-μg/ml range for both species. Against cysts, levofloxacin (Oftaquix) was cysticidal at 625 μg/ml.

Table 1. Efficacy of Topical Anesthetics and Fluorescein Sodium Against Acanthamoeba spp. Trophozoites and Cysts and Toxicity to a Human Epithelial Cell Line (Hep2)

| Drug                          | A. castellanii | A. polyphaga | Hep2 |
|-------------------------------|---------------|--------------|------|
|                               | MTIC | MTAC | MCC  | MTIC | MTAC | MCC  | MCT  |
| Proxymetacaine                | 39   | 156  | 156  | 39   | 78   | 156  | 39   |
| Tetracaine                    | 9.75 | 19.5 | 39   | 19.5 | 39   | 78   | 39   |
| Oxybuprocaine                 | 31.3 | 250  | 125  | 15.6 | 125  | 250  | 125  |
| Lidocaine (+fluorescein)      | 312  | 1,250| 10,000| 625  | 312  | 1,250| 5,000|
| Fluorescein sodium (2%)       | >10,000| >10,000| >10,000| >10,000| >10,000| >10,000| 1,250|

MCT, minimum cytotoxic concentration.
Table 2. Efficacy of Topical Antibiotics, Antivirals, and Preservatives Against *Acanthamoeba* spp. Trophozoites and Cysts and Toxicity to a Human Epithelial Cell Line (Hep2)

| Drug                              | In Vitro Drug Sensitivities (µg/ml) of: | A. castellanii | A. polyphaga | Hep2 MCT |
|-----------------------------------|----------------------------------------|---------------|---------------|----------|
|                                   |                                        | MTIC         | MTAC         | MCC      |          |
| Levofloxacin (Oftaquix)<sup>a</sup> |                                        | 78           | 156          | 625      | 156      |
| Levofloxacin (pure drug)          |                                        | 312          | 1250         | 2500     | 1250     |
| Moxifloxacin (Moxeza)             |                                        | 625          | 2500         | 2500     | 2500     |
| Chloramphenicol (pure drug)       |                                        | 312          | 625          | 2500     | 1250     |
| Chloramphenicol (generic)<sup>b</sup> |                                      | 78           | 312          | 625      | 39       |
| Aciclovir (pure drug)             |                                        | 63           | 125          | >500     | 125      |
| TFT<sup>c</sup>                   |                                        | 312          | 625          | 5000     | 156      |
| BAC                               |                                        | 3.9          | 7.8          | 15.6     | 1.95     |
| Phenylmercuric nitrate            |                                        | 1.95         | 3.9          | 31.3     | 1.95     |

<sup>a</sup> Compound is preserved with BAC (0.005% w/v).

<sup>b</sup> Compound is preserved with phenylmercuric nitrate (0.002% w/v).

<sup>c</sup> Compound is preserved with BAC (0.02% w/v).

Table 3. Efficacy of Diamidine Compounds Against *Acanthamoeba* spp. Trophozoites and Cysts and Toxicity to a Human Epithelial Cell Line (Hep2)

| Drug                              | In Vitro Drug Sensitivities (µg/ml) of: | A. castellanii | A. polyphaga | Hep2 MCT |
|-----------------------------------|----------------------------------------|---------------|---------------|----------|
|                                   |                                        | MTIC         | MTAC         | MCC      |          |
| Propamidine (pure drug)           |                                        | 62.3         | 250          | >500     | 250      |
| Propamidine (Brolene)<sup>a</sup> |                                        | 7.8          | 15.6         | 500      | 15.6     |
| Hexamidine (pure drug)            |                                        | 7.8          | 62.3         | 250      | 7.8      |
| Hexamidine (Desomedine)           |                                        | 7.8          | 62.3         | 250      | 7.8      |
| Pentamidine (pure drug)           |                                        | 62.3         | 250          | >500     | 125      |

<sup>a</sup> Compound is preserved with BAC (0.005% w/v).

Table 4. Efficacy of Biguanides and Povidone Iodine Compounds Against *Acanthamoeba* spp. for Trophozoites and Cysts and Toxicity to a Human Epithelial Cell Line (Hep2)

| Drug                              | In Vitro Drug Sensitivities (µg/ml) of: | A. castellanii | A. polyphaga | Hep2 MCT |
|-----------------------------------|----------------------------------------|---------------|---------------|----------|
|                                   |                                        | MTIC         | MTAC         | MCC      |          |
| PHMB                              |                                        | 1            | 3.9          | 15.6     | 1        |
| Chlorhexidine                     |                                        | 1            | 3.9          | 31.3     | 1.95     |
| Octenidine                        |                                        | 1            | 1.95         | 7.8      | 0.5      |
| Alexidine                         |                                        | 1            | 1.95         | 3.9      | 1.95     |
| Povidone iodine                   |                                        | 7.8          | 31.3         | 15.6     | 7.8      |

5
compared to levofloxacin (pure drug) and moxifloxacin, which showed cysticidal activity in the 2.5- to 5-mg/ml range. For the toxicity assay, levofloxacin (Oftaquix) and moxifloxacin gave a toxicity of 39 and 156 µg/ml, respectively. Two preparation of the chloramphenicol were tested. The preserved and preservative-free versions showed inhibitory activity against trophozoites at 39 to 312 µg/ml, whereas for the cysts this ranged from 312 µg/ml to 2.5 mg/ml for the two species of *Acanthamoeba*, respectively. Phenylmercuric nitrate, which is the preservative used in chloramphenicol, was active against trophozoites in the 1- to 3.9-µg/ml range and against cysts in the 15.6- to 31.3-µg/ml range. BAC, which is commonly added to ophthalmic preparations as a preservative, was active against trophozoites in the 1- to 7.8-µg/ml range and against cysts in the 7.8- to 15.6-µg/ml range.

The antiviral TFT was active against trophozoites in the 312- to 1250-µg/ml range and against cysts in the 2.5- to 5-mg/ml range. Aciclovir ophthalmic ointment (Zovirax) could not be used due to the soft paraffin base and so a solution was prepared from the pure drug. Aciclovir was active against trophozoites in the 63- to 250-µg/ml range but showed no activity against cysts in the range tested.

The effect of the biguanide compounds and povidone iodine against *Acanthamoeba* trophozoites and cysts and the toxicity to the mammalian cell line are shown in Table 4. In the trophozoite assay, all of the biguanides demonstrated inhibitory activity in the 0.5- to 1.95-µg/ml range and amoebicidal activity in the 1- to 15.6-µg/ml range. For cysticidal activity, the biguanides ranged from 3.9 to 31.3 µg/ml; both octenidine and alexidine were comparable to PHMB in terms of antimicrobial efficacy. For the toxicity assay, the biguanides ranged between 1 and 31.3 µg/ml, with PHMB demonstrating the highest value (least cytotoxic). Povidone iodine was active against trophozoites in the 7.8- to 31.3-µg/ml range and against cysts in the 7.8- to 15.6-µg/ml range.

The changes in the morphology of the cysts when exposed to various compounds taken with TEM are shown in Figure 1. As a control, a healthy Neff’s cyst in one-fourth-strength Ringer’s solution can be seen in Figure 1A. The healthy cyst has a thick cyst wall surrounding the encysted trophozoite. The trophozoite plasma membrane touches the endocyst wall, taking up the full space available inside the cyst. In the cytoplasm, the nucleus can clearly be seen as can the rounded structures, including mitochondria and lysosomes.

After exposure to tetracaine, the nucleus is no longer visible and the cytoplasm is full of micelles caused by the breakup of the nuclear membrane (Fig. 1B). With preserved chloramphenicol, propamidine pure drug, and unpreserved chloramphenicol, no changes in the intracellular organization of the cytoplasm and nucleus were observed, respectively (Figs. 1C, 1D, 1H).

With BAC (0.05 mg/ml), the plasma membrane of the encysted trophozoite has been damaged and shrunk away from the walls of the endocyst and there is a lack of a defined nucleolus and an increase in the number of cytoplasmic micelles consistent with membrane damage (Fig. 1E).

With povidone iodine (5% w/v) and PHMB, the plasma membrane of the encysted trophozoite has been severely damaged and has shrunk significantly away from the walls of the endocyst. No defined nuclear structures were seen, and there are large numbers of micellar aggregations inside the cyst suggesting complete plasma membrane destruction in the encysted trophozoite (Figs. 1F, 1G).

**Discussion**

AK is a sight-threatening corneal infection, and early diagnosis is paramount in achieving a better prognosis and visual outcome. Risk factor determination and clinical examination can often differenti-
ate AK from other forms of keratitis, with ring infiltrate or disease confined to the epithelium to be more common compared to bacterial and fungal keratitis.\(^{22}\) However, in epithelial disease, especially associated with dendritic-type lesions, *Acanthamoeba* can be misdiagnosed with other causes of keratitis, such as herpes simplex (HSV) keratitis.\(^{4,10}\) Traditionally, cultures have been the mainstay in diagnosing *Acanthamoeba*, but a low culture-positive rate\(^ {23}\) and prolonged incubation period often lead to a delay in

---

*Figure 1.* TEM images of *Acanthamoeba* cyst after 1-hour exposure to the following 7 agents: (A) untreated healthy cyst as control, (B) treated with 1% tetracaine, (C) treated with 0.5% preserved chloramphenicol, (D) treated with 0.1% propamidine pure drug, (E) treated with 0.05 mg/ml BAC, (F) treated with 5% povidone iodine, (G) treated with 0.02% PHMB, and (H) treated with 0.5% unpreserved chloramphenicol. *Bar:* 2 µm.
The use of in vivo reflectance confocal microscopy and PCR in diagnosing AK have shown good promise, with sensitivity values ranging between 56% and 100%, and 77% and 88%, respectively. The main advantages of IVCM are that it is noninvasive and it provides a rapid diagnosis, but the main limitations are the potential difficulty in differentiating pathogenic organisms from host cells and the diagnostic accuracy is dependent on observer experience. PCR testing is quicker and more sensitive than culture, returning a result often within days rather than weeks, but similar to cultures, false-negative results do occur. Possible factors include the amount of viable *Acanthamoeba* obtained from the corneal scrape or biopsy and an inhibition effect from the use of topical agents before microbiological sampling, such as prior empirical treatment with antibiotics, the use of anesthetics, and vital stains such as fluorescein. There are limited data on the inhibitory effect of topical anesthetics, with one study showing that proparacaine (proxymetacaine) did not adversely affect PCR, whereas in a second study, they found oxybuprocaine inhibited real-time PCR in detecting *Acanthamoeba*. We have found that the type of topical anesthetic greatly affected the viability of *Acanthamoeba* in that lidocaine had a much lower antimicrobial effect and, at therapeutic concentration, it did not exert significant antimicrobial activity against cysts and trophozoites for two species of *Acanthamoeba*. Although the lidocaine used in this study was combined with fluorescein, we did not find that testing fluorescein on its own had any major antimicrobial effect on the trophozoites or cysts. This contrasts with the other topical anesthetics, in particular tetracaine, which was observed to exert a much stronger antimicrobial effect against trophozoites and cysts of *Acanthamoeba* and toxicity to a human cell line. The antimicrobial effect of proxymetacaine was similar to oxybuprocaine for *A. castellanii*, but for *A. polyphaga*, proxymetacaine had a greater amoebicidal and cysticidal effect, in addition to being more toxic to the human cell line. These results suggest that the use of topical anesthetics, especially with tetracaine, can have a potent antiamoebic effect and it may be an important contributory factor in the reported low sensitivity for culture from corneal scrape.

Depending on the antibiotic protocol used, empirical treatment with third- or fourth-generation fluoroquinolones, due to their broad-spectrum antimicrobial activity, is often prescribed as an initial therapy for the treatment of microbial keratitis. We found that the pure drug of levofloxacin and a preservative-free preparation of moxifloxacin (Moxeza) did not exert any major antimicrobial effect on the viability of *Acanthamoeba*, whereas preserved levofloxacin (Oftaquix), which is preserved with BAC, had a much greater antimicrobial activity on both species of *Acanthamoeba*. This indicates it is the BAC in preserved levofloxacin rather than the drug itself that is causing the antimicrobial effect observed. Thompson and coworkers did not find any adverse effect on PCR amplification for *Acanthamoeba* with gatifloxacin or moxifloxacin. The gatifloxacin used in their study (Zymar; Allergan, Irvine, CA) was preserved with BAC, whereas the moxifloxacin was self-preserved. Although they did not test BAC on its own, the minimal inhibitory effect found with both antibiotics suggests that the effect of BAC on PCR in detecting *Acanthamoeba* DNA may be less compared to the amoebicidal and cysticidal assay methods used in this study.

Comparing the two preparations of chloramphenicol, the preserved drug had a much higher in vitro activity against *Acanthamoeba*, suggesting the antiamoebic effect is related to the preservative phenylmercuric nitrate. That said, the TEM images did not show much difference in the morphology with the preserved and preservative-free version of chloramphenicol.

This difference in antiamoebic activity was also seen when comparing preserved propamidine (Brolene), a common over-the-counter anti-infective ophthalmic preparation in the United Kingdom, with the pure drug propamidine. Previously, it has been shown that the concentrations of BAC typically found in ophthalmic medicines are highly toxic to *Acanthamoeba* trophozoites. In the study by Tu et al., exposing trophozoites to BAC concentrations in the 10- to 30-µg/ml range produced up to a 4.5-log reduction in viability over 6.5 hours. However, this present study is the first to observe the effect of BAC-containing preparations against the highly resistant cystic stage of *Acanthamoeba*. We found the MTIC, MTAC, and MCC for BAC were significantly lower than the concentration of the BAC present in both Brolene (50 µg/ml) and Oftaquix (50 µg/ml) ophthalmic preparations. Indeed, this study has demonstrated that the presence of the BAC preservative in propamidine (Brolene) eye drops is likely to be solely responsible for the observed antiamoebic activity. Two previous studies have reported MTAC values for propamidine of 5 to 25 µg/ml and 0.49 to 0.97 µg/ml, but in both studies they only used the benzalkonium-
preserved Brolene without comparing it to propamidine pure drug. This is the first study that has compared propamidine (pure drug) against BAC-preserved propamidine (Brolene), and we found the MTAC range for Brolene (15.6–31.3 μg/ml) to be similar to the study found by Hay et al. and higher than the values found in the study by Elder et al. However, when tested in the absence of BAC, the MTAC was much higher in the 250- to 500-μg/ml range (Table 2). This confirms that the antiamoebic activity of Brolene is down to the presence of BAC in the formulation. In fact, the amount of BAC in Brolene (50 μg/ml) is much higher than the MTAC found in this study, typically 12.8 times greater than the concentration observed to inhibit trophozoites. Morphologically, the TEM images show clear evidence that BAC causes damage to the cysts, and this is in agreement with the findings from Sunada et al. who found destruction of the cytoplasmic elements and separation of the inner and outer walls when cysts were exposed to BAC. However, in their study, the TEM cyst images with BAC and propamidine showed similar level of destruction of encysted trophozoite, and this is due to the fact that the authors did not use pure propamidine and instead they used GoldenEye eye drops that contain 0.1% w/v propamidine preserved with 0.05% BAC.

Many multidose ophthalmic preparations utilize BAC as a preservative to prevent contamination of the formulation; therefore, the empirical use of BAC preserved eye drops prior to a diagnosis of AK is likely to have a negative impact on the viability of Acanthamoeba present on the cornea, which may further contribute to the reported low positive culture rate for AK from corneal scrapes. Aciclovir demonstrated greater inhibitory and amoebicidal effect on trophozoites compared to TFT, but neither drug appeared to be effective against the cysts. Aciclovir is commonly used to treat HSV keratitis, and as AK is often misdiagnosed as HSV, the potential inhibitory effect on Acanthamoeba trophozoites would need to be considered.

When the experiments were repeated with hexamidine (Desomedine), another diamidine commonly used in the treatment of AK, we found that this gave identical results to hexamidine (pure drug). This result is not surprising as Desomedine, unlike Brolene, does not contain any preservatives. Moreover, this study has examined the activity of three different diamidines with increasing alkyl chain lengths between the aromatic benzene rings. The observation that the six-carbon hexyl chain length compound hexamidine has superior activity to the propyl and pentyl diamidines is consistent with a previous study showing that diamidine antiamoebic activity increases with lipophilicity due to increased interaction with the Acanthamoeba lipid bilayer.

The aim of this study was to assess the potential inhibitory effect of prior administration of commonly used topical agents on the viability of Acanthamoeba before microbiological sampling, but to obtain a sense of how potent these agents are, we also compared the in vitro susceptibility to current and potential new treatment for AK. The results obtained in this study for chlorhexidine and PHMB are consistent with previously published studies, with PHMB demonstrating superior activity to chlorhexidine. The standard topical PHMB used in treating AK is 0.02% (200 μg/ml), which is nearly 20 times the mean MCC for PHMB found in this study; the finding agrees with the general favorable in vitro sensitivities and clinical outcome with PHMB compared to other antiamoebic drugs. However, Sunada et al. did not find that their Acanthamoeba isolates had high in vitro susceptibility to PHMB. Furthermore, the TEM appearance of the cysts in this study seem to be more affected, with damage to the cyst plasma membrane clearly seen, compared to Sunada et al. who found mainly a loss of electron-dense material in the cytoplasm. We found both alexidine and octenidine demonstrated very good in vitro sensitivities, and in fact, octenidine was superior to PHMB for MTAC and MCC for both species of Acanthamoeba, although the toxicity against the mammalian cell line was comparatively higher. This is the first study that has reported the activity of octenidine against Acanthamoeba cysts and trophozoites. The results of this study on alexidine agree with a previous study that reported an MTAC of 10 μg/ml, although they observed a much higher MCC (100 μg/ml). The exact reason for this difference is unclear, but the concentration of cysts used in the Alizadeh et al. study was 100-fold greater at 1 × 10^6 compared to 1 × 10^4/ml used in this and other published studies. Neither alexidine and octenidine are currently used to treat AK in a clinical setting, but the favorable antimicrobial activity against both Acanthamoeba cysts and trophozoites, especially with octenidine, warrants further investigation, as they may be useful in patients who do not respond to standard anti-amoebic treatment. Alexidine, at a concentration of 1.6 μg/ml, is incorporated in one CL solution (AMO RevitaLens OcuTec), and it has been demonstrated that alexidine has excellent activity against cysts of
Acanthamoeba. Aside from Alexidine, the majority of the multipurpose CL solutions (MPS) utilizes PHMB alone or in conjunction with polyquaternium-1. The concentration of PHMB-containing MPS are in the order of 1 µg/ml, which is equivalent to the MTIC found in this study. Accordingly, the aim of these MPS is to provide effective disinfectant properties through the prevention and inhibition of pathogenic organisms on the CL or the CL case, and therefore, it is possible that the release of the biocide from the CL can exert an inhibitory effect on the viability of Acanthamoeba on the cornea. The uptake and release of biocides occur in all types of CLs, but the interaction is complex and varies with numerous factors; therefore, the potential inhibitory effect on Acanthamoeba with the release of biocide from CLs on the cornea is currently unknown.

We found that povidone iodine, as in other studies, demonstrated good in vitro activity on Acanthamoeba isolates, with clear signs of damage from the TEM images. In fact, the MCC activity was identical to PHMB and superior to both propamidine and hexamidine. Although povidone iodine is not routinely used prior to performing a cornea scrape, the potential inhibitory effect on the viability of Acanthamoeba must be borne in mind.

The main limitation of this study is that findings from in vitro sensitivities do not always correlate with clinical outcome. There are many factors to explain this. The cysticidal assay exposed the cysts to the testing compound and then reexamined them after 7 days for excystation and trophozoite replication. In a clinical setting, corneal scrape for culture is performed straight after the instillation of topical anesthetics or vital stain; therefore, a shorter assay period would be more representative. Although we tested two commonly used fluoroquinolones and chloramphenicol, prior empirical antimicrobial treatment for microbial keratitis varies with different institutions, so the in vitro sensitivities might be different with different antibiotics. In addition, the interaction of the epithelium with a drug and the penetration of it into the stroma would be different with different types of drugs. These are shortcomings in vitro sensitivity and efficacy studies of drugs on pathogens. Notwithstanding this, the potential adverse effect on the viability of Acanthamoeba with drugs used during clinical examination to reduce pain or the prior treatment with antibiotics before obtaining tissue specimens for culture or PCR need to be considered.

In conclusion, the present work indicates that the use of proxymetacaine, oxybuprocaine, and tetracaine to reduce pain; ophthalmic preparations containing preservatives such as BAC; and the use of povidone iodine prior to specimen sampling may affect the viability of Acanthamoeba in vivo, resulting in reduced culture yield and an inhibition effect on PCR amplification.

Acknowledgments

This study was supported by the Iraqi Ministry of Higher Education and Scientific Research for the PhD studentship of Anas Hamad and by a grant from the Sir Halley Stewart Trust.

Disclosure: S. Heaselgrave, None; A. Hamad, None; S. Coles, None; S. Hau, None

References

1. Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans. Clin Microbiol Rev. 2003;16:273–307.
2. Association of Contact Lens Manufacturers. ACLM Contact Lens Year Book 2016. Devizes, UK: ACLM; 2016.
3. Kilvington S, Gray T, Dart J, et al. Acanthamoeba keratitis: the role of domestic tap water contamination in the United Kingdom. Invest Ophthalmol Vis Sci. 2004;45:165–169.
4. Radford CF, Minassian DC, Dart JK. Acanthamoeba keratitis in England and Wales: incidence, outcome, and risk factors. Br J Ophthalmol. 2002;86:536–542.
5. Stehr-Green JK, Bailey TM, Brandt FH, Carr JH, Bond WW, Visvesvara GS. Acanthamoeba keratitis in soft contact lens wearers. A case-control study. JAMA. 1987;258:57–60.
6. Cope JR, Collier SA, Schein OD, et al. Acanthamoeba keratitis among rigid gas permeable contact lens wearers in the United States, 2005 through 2011. Ophthalmology. 2016;123:1435–1441.
7. Radford CF, Bacon AS, Dart JK, Minassian DC. Risk factors for acanthamoeba keratitis in contact lens users: a case-control study. BMJ. 1995;310:1567–1570.
8. Verani JR, Lorick SA, Yoder JS, et al. National outbreak of Acanthamoeba keratitis associated with use of a contact lens solution. United States. Emerg Infect Dis. 2009;15:1236–1242.
9. Tan SZ, Walkden A, Au L, et al. Twelve-year analysis of microbial keratitis trends at a UK tertiary hospital. *Eye (Lond).* 2017;31:1229–1236.
10. Carnt N, Robaei D, Minassian DC, Dart JKG. Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. *Br J Ophthalmol.* 2018;102:1431–1435.
11. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. *Am J Ophthalmol.* 2009;148:487–499.e482.
12. Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. *Am J Ophthalmol.* 2008;145:130–135.
13. Lorenzo-Morales J, Martin-Navarro CM, Lopez-Arencibia A, Arnalich-Montiel F, Pinero JE, Valladares B. Acanthamoeba keratitis: an emerging disease gathering importance worldwide? *Trends Parasitol.* 2013;29:181–187.
14. Polat ZA, Walochnik J, Obwaller A, Vural A, Dursun A, Arici MK. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. *Clin Exp Ophthalmol.* 2014;42:151–158.
15. Alexander CL, Coyne M, Jones B, Anijeet D. Acanthamoeba keratitis: improving the Scottish diagnostic service for the rapid molecular detection of Acanthamoeba species. *J Med Microbiol.* 2015;64:682–687.
16. Goh JWY, Harrison R, Hau S, Alexander CL, Tole DM, Avadhanam VS. Comparison of in vivo confocal microscopy, PCR and culture of corneal scrapes in the diagnosis of acanthamoeba keratitis. *Cornea.* 2018;37:480–485.
17. Goldschmidt P, Rostane H, Saint-Jean C, et al. Effects of topical anaesthetics and fluorescein on the real-time PCR used for the diagnosis of herpesviruses and Acanthamoeba keratitis. *Br J Ophthalmol.* 2006;90:1354–1356.
18. Seitzman GD, Cevallos V, Margolis TP. Rose bengal and Lissamine green inhibit detection of herpes simplex virus by PCR. *Am J Ophthalmol.* 2006;141:756–758.
19. Tu EY, Shoff ME, Gao W, Joslin CE. Effect of low concentrations of benzalkonium chloride on acanthamoebal survival and its potential impact on empirical therapy of infectious keratitis. *JAMA Ophthalmol.* 2013;131:595–600.
20. Kilvington S, Lam A. Development of standardized methods for assessing biocidal efficacy of contact lens care solutions against Acanthamoeba trophozoites and cysts. *Invest Ophthalmol Vis Sci.* 2013;54:4527–537.
21. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. *Cancer Commun.* 1991;3:207–212.
22. Mascarenhas J, Lalitha P, Prajna NV, et al. Acanthamoeba, fungal, and bacterial keratitis: a comparison of risk factors and clinical features. *Am J Ophthalmol.* 2014;157:56–62.
23. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. *Am J Ophthalmol.* 2006;142:1066–1068.
24. Bharathi MJ, Ramakrishnan R, Meenakshi R, Mittal S, Shivakumar C, Srinivasan M. Microbiological diagnosis of infective keratitis: comparative evaluation of direct microscopy and culture results. *Br J Ophthalmol.* 2006;90:1271–1276.
25. Chidambaram JD, Prajna NV, Larke NL, et al. Prospective study of the diagnostic accuracy of the in vivo laser scanning confocal microscope for severe microbial keratitis. *Ophthalmology.* 2016;123:2285–2293.
26. Hau SC, Dart JK, Vesaluoma M, et al. Diagnostic accuracy of microbial keratitis with in vivo scanning laser confocal microscopy. *Br J Ophthalmol.* 2010;94:982–987.
27. Tu EY, Joslin CE, Sugar J, Booton GC, Shoff ME, Fuerst PA. The relative value of confocal microscopy and superficial corneal scrapings in the diagnosis of Acanthamoeba keratitis. *Cornea.* 2008;27:764–772.
28. Kanavi MR, Javadi M, Yazdani S, Mirdeghammand S. Sensitivity and specificity of confocal scan in the diagnosis of infectious keratitis. *Cornea.* 2007;26:782–786.
29. Mathers WD, Nelson SE, Lane JL, Wilson ME, Allen RC, Folberg R. Confirmation of confocal microscopy diagnosis of Acanthamoeba keratitis using polymerase chain reaction analysis. *Arch Ophthalmol.* 2000;118:178–183.
30. Papsch G, Sharma S, Garg P, Aggarwal RK. Use of 18S rRNA gene-based PCR assay for diagnosis of acanthamoeba keratitis in non-contact lens wearers in India. *J Clin Microbiol.* 2003;41:3206–3211.
31. Thompson PP, Kowalski RP, Shanks RM, Gordon YJ. Validation of real-time PCR for laboratory diagnosis of Acanthamoeba keratitis. *J Clin Microbiol.* 2008;46:3232–3236.
32. Marangon FB, Miller D, Alfonso EC. Impact of prior therapy on the recovery and frequency of corneal pathogens. *Cornea.* 2004;23:158–164.
33. Elder MJ, Kilvington S, Dart JK. A clinicopathologic study of in vitro sensitivity testing and Acanthamoeba keratitis. *Invest Ophthalmol Vis Sci*. 1994;35:1059–1064.

34. Hay J, Kirkness CM, Seal DV, Wright P. Drug resistance and Acanthamoeba keratitis: the quest for alternative antiprotozoal chemotherapy. *Eye*. 1994;8:555–563.

35. Sunada A, Kimura K, Nishi I, et al. In vitro evaluations of topical agents to treat Acanthamoeba keratitis. *Ophthalmology*. 2014;121:2059–2065.

36. Kilvington S, Hughes R, Byas J, Dart J. Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates. *Antimicrob Agents Chemother*. 2002;46:2007–2009.

37. Perrine D, Chenu JP, Georges P, Lancelot JC, Saturnino C, Robba M. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. *Antimicrob Agents Chemother*. 1995;39:339–342.

38. Alizadeh H, Neelam S, Cavanagh HD. Amoebicidal activities of axelidine against 3 pathogenic strains of acanthamoeba. *Eye Contact Lens*. 2009;35:1–5.

39. Kilvington S, Huang L, Kao E, Powell CH. Development of a new contact lens multipurpose solution: Comparative analysis of microbiological, biological and clinical performance. *J Optom*. 2010;3:134–142.